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Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma, primary
effusion lymphoma, and multicentric Castleman’s disease. Kaposi’s sarcoma is the most common neoplasm
among human immunodeficiency virus-positive individuals. Like other herpesviruses, KSHV is able to estab-
lish a predominantly latent, life-long infection in its host. The KSHV lytic cycle can be triggered by a number
of stimuli that induce the expression of the key lytic switch protein, the replication and transcription activator
(RTA) encoded by Orf50. The expression of Rta is necessary and sufficient to trigger the full lytic program
resulting in the ordered expression of viral proteins, release of viral progeny, and host cell death. We have
characterized an unknown open reading frame, Orf49, which lies adjacent and in the opposite orientation to
Orf50. Orf49 is expressed during the KSHV lytic cycle and shows early transcription kinetics. We have mapped
the 5 and 3 ends of the unspliced Orf49 transcript, which encodes a 30-kDa protein that is localized to both
the nucleus and the cytoplasm. Interestingly, we found that Orf49 was able to cooperate with Rta to activate
several KSHV lytic promoters containing AP-1 sites. The Orf49-encoded protein was also able to induce
transcriptional activation through c-Jun but not the ATF1, ATF2, or CREB transcription factor. We found that
Orf49 could induce phosphorylation and activation of the transcription factor c-Jun, the Jun N-terminal kinase
(JNK), and p38. Our data suggest that Orf49 functions to activate the JNK and p38 pathways during the KSHV
lytic cycle.
Kaposi’s sarcoma-Associated herpesvirus (KSHV) is etio-
logically linked to Kaposi’s sarcoma (12, 17, 25), primary effu-
sion lymphoma, and multicentric Castleman’s disease (3, 4).
Kaposi’s sarcoma is the leading neoplasm in human immuno-
deficiency virus-positive individuals. KSHV is the most re-
cently described human herpesvirus, identified in 1994 by
Chang et al. (6) via representational difference analysis. A
member of the gamma subfamily of herpesviruses, KSHV is
also the only known human rhadinovirus.
Like other herpesviruses, KSHV can establish both latent
and lytic infection in its host. The lytic program can be trig-
gered by a number of stimuli that induce the expression of the
lytic switch protein, the replication and transcription activator
(RTA) encoded by Orf50 (38). The expression of RTA is
necessary and sufficient to trigger the full lytic program (21, 22)
resulting in the ordered expression of all viral proteins, release
of viral progeny and host cell death. RTA/Orf50 initiates the
lytic cascade by inducing the transcriptional activation of viral
promoters such as PAN, ORF6 (single-stranded-DNA-binding
protein), K1, K2 (viral interleukin-6), K5, K6 (viral MIP-1), K8
(MTA), K9 (viral IRF), ORF57 (MTA), ORF50 (RTA), thy-
midine kinase, K12 (kaposin), K14 (viral OX-2), and ORF74
(viral G protein-coupled receptor) (5, 7, 9, 10, 16, 20, 21, 33, 37,
39, 44). This wide range of promoter activation occurs through
sequence-specific binding of Orf50 to DNA via RTA respon-
sive elements (5, 9, 20, 37) and binding to cellular transcription
factors such as C/EBP- and RBPJ- (19, 41).
Another protein expressed in the lytic cascade is K8 or
K-bZIP, a structural and positional homologue of Epstein-
Barr virus ZTA. However, unlike Epstein-Barr virus ZTA,
K-bZIP is unable to activate lytic transcription from latency
(30). K-bZIP shows strong trans-repression of viral ORF50
(15) and cellular p53 (28) promoters. Sumoylation of K8 me-
diates its repression (14).
Studies on KSHV pathogenesis have been limited to latently
infected primary effusion lymphoma-derived B-cell lines such
as BCBL-1, BC-2, JSC-1, BC-3 and BC-1. In these cell lines,
latency can be disrupted by the addition of the phorbol ester
12-O-tetradecanoylphorbol 13-acetate (TPA) or the histone
deacetylase inhibitor sodium butyrate (24, 32). However, the
efficiency of reactivation as measured by viral particle produc-
tion, is very low, peaking at approximately twenty percent (42).
Moreover, studies of KSHV latency are complicated by the
fact that, at any time, 5% of these cells are undergoing
spontaneous lytic reactivation.
In an effort to enhance our understanding of KSHV path-
ogenesis, we focused our attention on Orf49, an uncharac-
terized open reading frame in the lytic switch locus. Orf49 is
located adjacent to Orf50 and on the opposite strand. The
gene encoded by Orf49 shows limited sequence homology to
the Epstein-Barr virus BRRF1 gene. Epstein-Barr virus
BRRF1 lies in the same relative orientation as KSHV Orf49
and is subject to a similar splicing event that omits the
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BRRF1 sequence from the Epstein-Barr virus RTA tran-
script (34).
Here we describe the initial characterization of KSHV Orf49
and its encoded protein. We have identified the 5 and 3 ends
of the Orf49 transcript using rapid amplification of cDNA ends
(RACE) and have characterized its transcription kinetics. The
Orf49-encoded protein by itself could not activate any of the
KSHV promoters we tested by promoter reporter assays, but it
was able to cooperate with KSHV Orf50 to activate a number
of lytic promoters containing AP-1 sites. We also found that
Orf49 can activate the c-Jun and the JNK/p38 pathways. We
suggest that Orf49-mediated activation of the p38/JNK path-
way during lytic reactivation plays an important role in KSHV
viral replication.
MATERIALS AND METHODS
Cell culture. Cos-1, 293, and HeLa cells were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, penicillin and
streptomycin, and 1 Gluta-max. CV-1 cells were further supplemented with
nonessential amino acids. Rhesus fibroblasts (RhF) were cultured in Dulbecco’s
modified Eagle’s medium with 10% Cosmic calf serum, penicillin and strepto-
mycin, and 1 Gluta-max. The BCBL-1 cell line was grown in RPMI 1640
medium with 10% fetal bovine serum, penicillin and streptomycin, and L-glutamine.
The BC-1 cell line was further supplemented with sodium pyruvate. All cell lines
were maintained at 37°C and 5% CO2. BCBL-1 and BC-1 cells were induced into
lytic reactivation by treating with 25 ng/ml phorbol-12-tetradecanoate-13-acetate or
mock treated with the carrier dimethyl sulfoxide (DMSO). Transient transfections
were carried out with the Superfect (QIAGEN) reagent according to the manufac-
turer’s directions.
Plasmids. KSHV Orf49 was PCR amplified from the DNA of BCBL-1 cells
induced with TPA for 48 h using primers 5 GCGGCGGAATTCATGGACTAC
AAGGACGACGACAAGACATCGAGAAGGCCCC and 3 CGCCGCAGA
TCTACCTTTTTATTGTATACTGAACAATGC. The 5 primer added a Flag
epitope to the PCR product, which was subsequently cloned into the pSG5 vector
(Stratagene). The Orf50 cDNA plasmid was amplified with primers 5 CGCCGC
GAATTCATGGCGCAAGATGACAAGGGTAAGAAGCTTCGGCGGTCC
and 3 CGCCGCAGATCTTTAACACTTGTCGTCGTCGTCCTTGTAGTC
GTCTCGGAAGTAATTACGCC, tagged with Flag at the C-terminal end and
cloned into pSG5. The orf50p, Orf57p, K8p, vIL-6p and vPolymerase promoter
reporter constructs have been described previously (16, 19–22) and encode a
viral promoter, which drives expression of the firefly luciferase gene in the
pGL3-Basic vector (Promega). Transcription factor plasmids, also described
previously (13), encode Gal-4, ATF1, ATF2, CREB, or c-Jun fused to the Gal4
DNA-binding domain. The E1B-CAT reporter plasmid contains five copies of
the Gal4 DNA-binding site upstream of the E1B TATA box and chloramphen-
icol acetyltransferase (CAT) gene.
5 and 3 rapid amplification of cDNA ends. Total RNA from TPA-induced
BCBL-1 cells was reverse transcribed using the Smart RACE cDNA amplifica-
tion kit (Clonetech) with random hexamer primers. The product was used as
template in a PCR with one of the following Orf49 specific primers (5-1 CTT
GACCAAAGCCGCGGAACCTAGGT, 5-2 GGAATAAGCCAAATTCCGCCC
TAGCCGC, 3-1 TGTCGTTCAGATGTACCAGCGGTGCA, and 3-2 GTCCGT
CGCCACCCTCAATCCAGACT). 5 and 3 PCR products were cloned into
pCR2.1-TOPO vector (Invitrogen) and individual colonies were sequenced.
RNA extractions and Northern blots. Total cellular RNA extractions were
performed with the RNA STAT-60 reagent (Tel-Test) according to the manu-
facturer’s instructions. Ten micrograms total RNA per sample was electropho-
resed in 1.5% agarose-formaldehyde gels and transferred to nitrocellulose mem-
branes (Hybond N; Amersham Pharmacia) by capillary transfer for 16 to 20 h.
Radioactive probes were made by random-primed oligonucleotide labeling
(Random Primed DNA-labeling kit, Roche) of gel-purified PCR products with
[-32P]dCTP (GE Healthcare). All hybridizations were performed using Quick-
hyb solution (Stratagene) for 16 to 20 h at 60°C in a rotating hybridization oven.
Membranes were washed twice in 2 SSC (1 SSC is 0.14 M NaCl plus 0.015
sodium citrate)–0.1% sodium dodecyl sulfate (SDS) for 15 min at room temper-
ature and once with 0.1 SSC–0.1% SDS for 30 min at 60°C. Membranes were
then analyzed with a PhosphorImager (Molecular Dynamics).
Western blots. Transfected cells in 100-mm dishes were washed twice with
phosphate-buffered saline (PBS) harvested with 200 l radioimmunoprecipita-
tion assay (RIPA) buffer (150 mM NaCl, 1%NP-40, 50 mM Tris [pH 6.8], 0.5%
sodium deoxycholate, 0.1% SDS) and freeze-thawed three times. Cell debris was
spun down and the supernatant was quantitated by Bradford assay (Bio-Rad).
Cell lysates were incubated with SDS gel loading buffer at 95°C for 5 min, on ice
for 1 min, and submitted to SDS-polyacrylamide gel electrophoresis (8).
For glycosylation experiments tunicamycin (Sigma) was added to cells to a
final concentration of 20 ng/ml or mock treated with an equal volume of carrier
and harvested after 48 h for Western blot analysis. Phosphatase treatments of
whole-cell lysates were performed following incubation with monoclonal anti-
Flag antibody (Sigma) for 1 h at room temperature and immunoprecipitation for
16 h at 4°C with AG beads (Santa Cruz). Beads were spun down and resuspended
in 100 l NEB buffer 3 and three microliters of calf intestinal phosphatase (New
England Biolabs) or PBS followed by incubation for 1 hour at 37°C. Electropho-
resed gels were transferred to nitrocellulose membranes (Hybond, Amersham)
in a semidry transfer apparatus (Bio-Rad) at constant 20 V for 1 h and blocked
in 5% dry milk, 1% Tween 20 Tris-buffered saline (TBSt) for 1 h at room
temperature.
Peroxidase-labeled antibody to Flag epitope (Sigma), total and phosphory-
lated c-Jun, -actin (Cell Signaling), and total and phosphorylated JNK antibod-
ies (Upstate) were used at 1:1.000 dilutions in TBSt or 5% milk–TBSt. Mem-
branes were washed three times for 5 min and immunoblots were detected with
the SuperSignal chemiluminescent substrate (Pierce). For fractionation assays
transfected cells were washed twice with 1 PBS and trypsinized for 5 min at
37°C. Trypsin was inactivated by adding an equal volume of complete growth
medium (5% serum) and kept on ice. Cells were washed with PBS, supernatants
were removed and cells were resuspended in 500 l cytosolic lysis buffer con-
taining 5 mM piperazine-N,N-bis(2-ethanesulfonic acid) (PIPES, pH 8.0), 85
mM KCl, and 0.5%NP-40, followed by a 5-min incubation on ice. Nuclei were
spun down and the cytosolic fraction was removed. The nuclear fraction was
washed with PBS, spun down, and lysed with RIPA buffer. Finally, both fractions
were freeze-thawed thrice and cleared by centrifugation.
Immunofluorescence assays. Cos-1, CV-1, and RhFs were seeded in six-well
plates and transfected with 4 g DNA per well. Forty-eight hours posttransfec-
tion cells were washed twice with 1 TBS and fixed in 1:1 methanol-acetone at
room temperature for 1 min. Cells were washed four times with TBS and
incubated with 1:1,000 anti-Flag Cy3 (Sigma) in TBS for 1 h at room tempera-
ture. 4,6-Diamidino-2-phenylindole (DAPI) in PBS was added for 10 min
followed by two more washes in TBS. Fluorescence was assayed in a Zeiss
Axiovert 200 inverted microscope.
Promoter reporter assays. Six-well plates seeded with CV-1 cells were cotrans-
fected with 1.5 g promoter reporter construct and 1.5 g of pSG5, pSG5-Orf49,
or pSG5-Orf50 cDNA. One microgram of -galactosidase expression plasmid
was cotransfected into each sample to normalize for transfection efficiency. Each
sample was analyzed in duplicate in at least two experiments. Forty-eight hours
posttransfection cells were washed once in cold 1 PBS and lysed by freeze-
thawing in 1 reporter lysis buffer (Promega). Lysates were analyzed for lucif-
erase activity with the luciferase assay system (Promega) and for -galactosidase
activity with the Galacto-Star kit (Tropix) in a FLUOstar plate reader (BMG
labtech).
Chloramphenicol acetyltransferase enzyme-linked immunosorbent assays.
CV-1 cells were seeded in six-well plates and cotransfected with 1.2 g E1B-
CAT, 1.2 g of transcription factor reporter, and 1.2 g pSG5 or pSG5-Orf49;
0.6 g of -galactosidase expression plasmid was added to each sample to
normalize for transfection efficiency. Forty-eight hours posttransfection cells
were washed three times in cold 1 PBS and lysed. Cell lysates were spun down
and incubated with a CAT enzyme-linked immunosorbent assay (ELISA) kit
(11) in Microwell plates according to the manufacturer’s recommendations. CAT
expression was assayed using a FLUOstar plate reader (BMG labtech).
RT-PCR. c-Jun N-terminal kinase (JNK) inhibitor SP600125 or p38 inhibitor
SB202190 (Sigma Aldrich) was added to a final concentration of 20 M to
BCBL-1 cells and simultaneously induced with TPA or mock induced with
DMSO. RNA was harvested 24 h postinduction using the RNA STAT-60 reagent
(Tel-Test) according to the manufacturer’s instructions and equal amounts were
reverse transcribed with the reverse transcription system kit (Promega). The
product was diluted 10- to 50-fold and used as the template for PCRs with
primers to viral GPCR, Orf57 (MTA), Orf49, LANA, and cellular glyceralde-
hyde-3-phosphate dehydrogenase.
RESULTS
Identification of the Orf49 transcript. In an effort to identify
the Orf49 transcript we performed 5 and 3 rapid amplifica-
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tion of cDNA ends. Total RNA was isolated from TPA-in-
duced BCBL-1 cells and used as the template for an initial
reverse transcription step. Gene-specific primers were then
used to amplify, clone, and sequence Orf49 cDNA. We de-
signed Orf49-specific primer sets to amplify the 5 and 3 ends
of Orf49 cDNAs and produce a 200-bp region of overlap be-
tween them enabling the alignment of the 5 and 3 clone
sequences (Fig. 1A). The PCR products (Fig. 1B) were cloned
into the TOPO 2.1 vector (Invitrogen). Since the length of
Orf49 is about 930 bp, we were able to produce sequence
alignments of the full-length Orf49 transcript including a short
5 untranslated region (UTR) and the 3 polyadenosine tail
(Fig. 1C). As depicted in Fig. 1C, the full-length Orf49 tran-
script is not spliced and the coding sequence is identical to the
genomic open reading frame.
Kinetics of expression of Orf49. In order to map the expres-
sion kinetics of Orf49 we induced BCBL-1 cells with 25 ng/ml
TPA or vehicle (DMSO) and harvested total RNA at 12, 24,
36, 48, and 72 h postinduction. Ten micrograms of total RNA
per sample was electrophoresed on an agarose-formaldehyde
gel and the resolved RNAs were transferred to nitrocellulose.
Northern blot analysis was performed with an Orf49 probe.
Figure 2 (upper panel) shows that Orf49 RNA is only tran-
scribed in TPA-induced cells and not in the DMSO-treated
cells. Orf49 was observed in two different transcripts, 3.6 and
1.2 kb in size. The 1.2-kb transcript is very close in size to the
predicted size of Orf49 while the 3.6-kb band likely represents
a polycistronic transcript. The Orf49 transcripts were readily
detectable at 12 h postinduction, indicating that this gene is
transcribed with early kinetics. The signal peaked between 24
and 36 h postinduction and remained high at 48 and 72 h. A
Northern blot with the Orf50-specific probe was included
(middle panel) in order to demonstrate efficient reactivation.
The lower panel in Fig. 2 shows the agarose gel with equal
loading of the individual RNA samples. Orf49 thus encodes a
lytic protein that is transcribed with early kinetics and to high
levels.
Characterization of the Orf49 protein. The cDNA for KSHV
Orf49 was PCR amplified and a Flag epitope was inserted at
the N terminus of the protein. The PCR product was then
FIG. 1. Delineation of the full-length Orf49 transcript. A) RT-PCR
design. Schematic representation of the Orf49 coding region (top) and
location of RT-PCR primers designed for 5 and 3 RACE (arrow-
heads). B) Molecular cloning of RT-PCR products. Ethidium bromide
visualization of RT-PCR products. Marker band sizes are provided on
the right. Lanes 5-1 and 5-2 yielded products of 900 and 350 base
pairs, respectively. Lanes 3-1 and 3-2 yielded products of 340 and
850 bp, respectively. Lane M, markers. Lane , primers 5-1 and 3-2
yield an internal fragment of 750 bp. Lane 	, negative control (no
reverse transcriptase). C) Sequence of the full-length Orf49 transcript
with 5 and 3 UTRs. RT-PCR products were cloned, sequenced, and
aligned. A short 5 UTR and a 3 poly(A) tail are underlined. The
transcript is not spliced and therefore identical to the genomic coding
sequence.
FIG. 2. Expression kinetics of Orf49. BCBL-1 cells were induced
into lytic reactivation with 25 ng/ml TPA or mock treated with DMSO.
Total RNA was harvested at 12, 24, 36, 48, and 72 h postinduction and
10 g RNA was loaded per well of a formaldehyde-agarose gel. North-
ern blot analysis with an Orf49-specific probe reveals two Orf49 tran-
scripts (upper panel), a longer, 3.6-kb transcript and a shorter 1.2-kb
species. Middle panel: Northern blot with an Orf50-specific probe to
demonstrate reactivation. Lower panel: loading control as visualized
by ethidium bromide staining of the formaldehyde-agarose gel prior to
transfer onto the nitrocellulose membrane.
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cloned into the pSG5 (Stratagene) vector and transfected into
Cos-1 cells. Orf49 ran as a 30-kDa protein on sodium dodecyl
sulfate (SDS)- polyacrylamide gel electrophoresis (PAGE). Se-
quence analyses of Orf49 suggested several possible N-linked
glycosylation and phosphorylation sites but no significant sim-
ilarity to other known proteins or cellular localization signals.
The glycosylation state of Orf49 was determined by treating
cells with tunicamycin, an inhibitor of N-glycosylation, for 48 h
and performing an Orf49 Western blot. Tunicamycin treat-
ment did not change the electrophoretic profile compared to
mock treatment, suggesting that Orf49 is not N-glycosylated
(data not shown).
In order to identify the phosphorylation state of the Orf49
protein we transiently transfected Cos-1 cells with the Orf49-
Flag plasmid and immunoprecipitated the lysates with anti-
Flag monoclonal antibody. Lysates were either treated with
phosphatase or mock treated with PBS followed by Western
blotting with anti-Flag antibody. There was no difference in
migration between phosphatase-treated versus mock-treated
cell lysates, suggesting that the protein may not be phospho-
rylated (data not shown). However it is possible that if phos-
phorylated, the protein is either resistant to calf intestinal
phosphatase treatment or the mobility shift is too small to be
detected by conventional SDS-PAGE.
We next determined the intracellular localization of the
Orf49-encoded protein. Cos-1 cells and rhesus fibroblasts were
transfected or mock transfected with Orf49 plasmid. Cos-1
cells were harvested using a cell fractionation method in order
to separate the cytoplasmic and nuclear fractions of lysates.
The nuclear and cytoplasmic samples and a nonfractionated,
total protein sample were subjected to Western blot with Flag
antibody. As shown in Fig. 3, the Flag-tagged Orf49 protein is
detectable in the nucleus of Cos-1 cells as well as in the cyto-
plasm. We used the cytoplasmic marker GRP-78 (35) as a
control for the stringency of the cell fractionation method to
show that there was no detectable cytoplasmic contamination
in the nuclear fraction.
For immunofluorescence we chose rhesus fibroblast (RhF)
cells because of their elongated shape and clear demarcation
of the nucleus and cytoplasm. At 48 h posttransfection RhFs
were subjected to immunofluorescence assays using an anti-
Flag antibody conjugated to Cy3 dye and DAPI, a nuclear
stain. We found that Orf49 was present in both the cytoplasm
and nucleus. Figure 4 shows immunofluorescence of Orf49 in
the RhF cells. Panels a and e show bright-field images of the
cells, panels b and f represent Orf49 staining, while panels c
and g represent nuclear staining with DAPI. A merged view of
Orf49 and nuclear staining is shown in panels d and h. We
observed similar cellular localization profiles for Orf49 in CV-1
and 293 cells (data not shown).
Orf50-mediated activation of key lytic promoters is en-
hanced by Orf49. Since Orf49 was expressed with early kinetics
and appeared to be both nuclear and cytoplasmic, we at-
tempted to determine if it could activate expression from a
number of KSHV lytic promoters. We cotransfected a set of
promoter-luciferase reporter constructs including Orf57p, viral
G protein-coupled receptor promoter (vGPCRp), and K8p
with cDNA expression plasmids for either Orf50, Orf49 or
both. Although Orf49 was in itself unable to achieve high levels
of activation of any of the promoters tested, we observed a
cooperative effect of Orf49 with Orf50 on the activation of
FIG. 3. Cell fractionation of Orf49-transfected cells. Cos-1 cells
were transfected with Orf49-Flag and separated into nuclear and cyto-
plasmic fractions. Equal amounts of protein were loaded onto SDS-
PAGE gels and transferred to nitrocellulose and the blots were probed
with Flag antibody. The upper panel shows Orf49-Flag expression in
the nucleus (Nuc.) and the cytoplasm (Cyto.). The lower panel shows
expression of GRP-78, a bona fide cytoplasmic marker.
FIG. 4. Cellular localization of Orf49. Rhesus fibroblasts were
transfected with an expression vector encoding a Flag-tagged Orf49
protein and 48 h later, cells were fixed and stained with the nuclear
DAPI stain (blue) and a Cy3-conjugated antibody to the Flag epitope
(red). Orf49 is readily detected in both the nucleus and cytoplasm of
the cell. Panels a and e: phase contrast; panels b and f: Cy3; panels c
and g: DAPI; panels d and h: merged DAPI and Cy3 stains. Panels a
to d, 40 magnification; panels e to h, 100 magnification.
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Orf57p, vGPCRp, and K8p (Fig. 5). Orf49 could augment
Orf50-mediated transactivation of these promoters.
It is important to note that Orf50-mediated induction of
these promoters ranged from 50- to 300-fold over that of
empty plasmid, arguing for a strong enhancing effect by Orf49
over an already high level of expression. (Fig. 5). There was no
cooperation with Orf50 on the induction of the viral interleu-
kin-6, Orf50, Pan (nut-1), and viral DNA polymerase promot-
ers by Orf49 (data not shown). Closer inspection of the pro-
moter sequences cooperatively activated by Orf50 and Orf49
revealed that they all contain AP-1 sites, raising the possibility
that Orf49 may augment Orf50 transcription in an AP-1-de-
pendent manner.
Orf49 can enhance c-Jun transcriptional function. In order
to determine if Orf49 could activate transcription factors
through the activation of AP-1 sites, we performed chloram-
phenicol acetyltransferase reporter assays with a c-Jun re-
porter plasmid. We examined whether Orf49 could augment
the function of ATF-1, ATF-2, CREB, or c-Jun fusion proteins
linked to the Gal4 DNA binding domain. Orf49 was cotrans-
fected with ATF-1, ATF-2, CREB-1, or c-Jun Gal4 protein
fusion expression plasmids into CV-1 cells, and the activation
of a reporter plasmid containing five copies of the Gal4 DNA
binding site upstream of the CAT gene was measured by a
CAT ELISA.
As shown in Fig. 6, Orf49 was unable to activate transcrip-
tion through the ATF1, ATF2, and CREB transcription fac-
tors. However, there was a dose-dependent, 5-fold induction
of the c-Jun transcription factor over that of empty plasmid.
Since the DNA binding activity in this experiment was medi-
ated through the Gal4 DNA binding domain of the individual
fusion proteins, these results suggest that Orf49 activates pro-
moters by enhancing c-Jun transcriptional function. Moreover,
the selective activation of c-Jun but not other transcription
factors could explain why Orf49 was able to enhance Orf50
induction of only those promoters with AP-1 sites, given that
c-Jun is one of the strongest activators of AP-1 elements.
Orf49 is capable of inducing c-Jun phosphorylation. The
activation of c-Jun is attributed to the phosphorylation of
serine residues 63 and 73 (31, 36). In order to confirm that
c-Jun was activated in cells expressing Orf49, we transfected
CV-1 cells with an Orf49 expression plasmid and harvested
protein lysates in the presence of phosphatase inhibitors. West-
ern blot analyses were performed using antibodies against total
c-Jun or c-Jun phosphorylated at both serine residues 63 and
73 to determine the phosphorylation and activation state of
c-Jun in the presence and absence of Orf49. Figure 7A shows
that c-Jun phosphorylation is greatly increased in the presence
of Orf49 compared to the empty-vector control.
c-Jun phosphorylation is mediated by c-Jun N-terminal ki-
nase. We transfected 293 cells with an Orf49 expression plas-
mid and performed Western blots to determine if JNK kinase
was activated in the presence of Orf49. JNK activation can be
measured by the phosphorylation status of threonine 183 and
tyrosine 185 residues (18). We found that Orf49 was in fact
able to induce the phosphorylation of JNK in 293 cells (Fig.
7B), leading to the activation of c-Jun and c-Jun-mediated
transcription. In addition, p38 kinase, another member of the
mitogen-activated protein (MAP) kinase family, was also phos-
phorylated and activated in Orf49-expressing cells compared
to the vector control (Fig. 7B).
In order to ascertain if JNK and p38 are indeed activated in
the more physiologically relevant context of reactivation of
latently infected B cells, we used a BCBL-1 cell line in which
the lytic switch RTA is inducible by tetracycline (26). In these
cells RTA expression is tightly regulated by tetracycline (or
doxycycline) and upon induction follows the strict pattern of
gene expression characteristic of herpesviruses. Western blots
for phospho-JNK and phospho-p38 were performed on lysates
from the RTA-TREX BCBL-1 cells and the negative control
pcDNA-TREX BCBL-1 cells, with or without a 24-h doxy-
cycline induction (final concentration of 1 g/ml). Western
blots for RTA were also performed to demonstrate the doxy-
cycline-mediated induction of RTA. As shown in Fig. 7C, both
JNK and p38 are activated after induction of RTA-TREX
BCBL-1 cells but not pcDNA-TREX BCBL-1 cells, thus dem-
onstrating that RTA-induced lytic reactivation does induce
phosphorylation/activation of JNK and p38 kinases and that
FIG. 5. Orf49 enhances Orf50-mediated induction of K8, Orf57,
and vGPCR lytic promoters. Promoter reporter assays: empty vector
(pSG5), Orf50, Orf49, or Orf50 plus Orf49 expression constructs were
cotransfected into CV-1 cells with plasmids in which the vGPCR, K8,
and Orf57 lytic promoters drive luciferase expression and 48 h post-
transfection, promoter activity was determined by luciferase assay.
Luciferase activities were normalized to -galactosidase and expressed
as fold induction over empty plasmid. Fold activation values are indi-
cated above each bar along with the standard error. Each experiment
was performed in duplicate and the experiment was repeated several
times.
FIG. 6. Orf49 enhances c-Jun transcriptional function. pSG5 empty
vector or Orf49 expression plasmids were cotransfected into CV-1 cells
with plasmids encoding five copies of the Gal4 binding site upstream of
the CAT gene and Gal4 protein fusions of ATF1, ATF2, CREB, and
c-Jun. Orf49 enhanced c-Jun-mediated transcription in a dose-depen-
dent manner but did not affect ATF-1, ATF-2-, or CREB-dependent
transcription function.
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our results are not an artifact of TPA-induction or transient
transfection.
Taken together these results define the mechanism by which
the Orf49 protein activates c-Jun-mediated transcriptional ac-
tivation, by eliciting the phosphorylation and activation of
JNK/p38 MAP kinases.
JNK/p38 activation is necessary for the expression of lytic
proteins. In order to determine the effect of JNK/p38 on
KSHV lytic reactivation and replication, BCBL-1 cells were
induced with TPA and simultaneously treated with the JNK
inhibitor SP600125 or p38 inhibitor SB202190. Total RNA was
harvested at 24 h postinduction and reverse transcribed. The
reverse transcription product was then diluted 10- to 50-fold
and used as the template in a PCR with primer sets for the
early lytic genes vGPCR, Orf57, and Orf49 as well as KSHV
LANA and human glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) controls. Figure 8A shows the PCR products
from these reactions. Both inhibitors seemed to decrease the
levels of lytic expression of the vGPCR and Orf57 transcripts.
The Orf49 transcript was unchanged in the presence of inhib-
itors, suggesting that Orf49 expression is not refractory to JNK
and p38 inhibition. The LANA and GAPDH controls were
stable regardless of treatment or replicative state.
We also performed Western blots to examine the expression
of late lytic proteins. BC-1 cell lysates were harvested 24 h after
treatment and equal amounts of protein were analyzed by
Western blot with anti-KSHV Orf62 antibody. Orf62 is also
called minor capsid protein or TRI-1 (27). As shown in Fig. 8B,
treatment with both JNK and p38 inhibitors suppressed lytic
reactivation as measured by expression of Orf62 protein. In
summary, these results support a functional role for the JNK
and p38 pathways in lytic reactivation.
DISCUSSION
We report here the first characterization of KSHV Orf49
located between the exons coding for Orf50 and on the oppo-
site strand. We performed 5 and 3 RACE to identify the ends
of the Orf49 transcript and found it to be unspliced. The Orf49
transcript was 1,000 base pairs long, containing the expected
coding sequence of over 900 bases plus a 15-nucleotide 5 UTR
and a 67-nucleotide 3 UTR including the poly(A) tail. North-
ern blot analyses revealed that Orf49 transcripts were highly
expressed during lytic reactivation with early kinetics and
throughout the length of TPA treatment. Two transcripts were
detected with an Orf49-specific probe, one of 1.2 and a second
of 3.6 kb. The 1.2-kb transcript corresponds closely to our
full-length cDNA clone. However, it is possible that there are
longer, possibly bicistronic, transcripts that we did not detect
via RACE. Expression levels peaked at 36 h post-TPA induc-
tion by Northern blot analyses. These results are similar to
those reported by others (29; Dirk Dittmer, personal commu-
FIG. 7. Orf49 induces phosphorylation of c-Jun by activation of
JNK and p38. A) CV-1 cells were transfected with the enhanced green
fluorescent protein (EGFP)vector or an Orf49 expression plasmid and
cells were harvested and lysed 48 h posttransfection. Phospho-c-Jun
levels increased in the presence of Orf49 (first panel) while total c-Jun
levels (second panel) remained comparable. The third panel shows
expression of Orf49. Actin expression is also shown in the bottom
panel to indicate equivalent loading. B) Both JNK and p38 pathways
are activated by Orf49. 293 cells were transfected with pSG5 vector or
Orf49 expression plasmids, serum starved for 24 h, and harvested 48 h
posttransfection. Lysates were subjected to Western blot analysis with
anti-phospho-JNK (pJNK) and anti-phospho-p38 (pp38) antibodies.
Cells expressing Orf49 (as determined by Western blot with anti-Flag)
showed vastly increased levels of phospho-JNK and phospho-p38 com-
pared to the empty-vector control. Actin expression is also shown in
the bottom panel to indicate equivalent loading. C) JNK and p38 are
activated during reactivation. pcDNA-TREX-BCBL-1 cells carrying
pcDNA (empty) vector or RTA-TREX-BCBL-1 cells carrying a doxy-
cycline-inducible RTA were treated with 1 g/ml doxycycline or
untreated for 24 h. Lysates were harvested and Western blots for
phospho-JNK, phospho-p38, and Orf50 were performed. Doxycycline-
induced RTA-TREX BCBL-1s showed increased levels of both phos-
pho-JNK and phospho-p38, while pcDNA-TREX BCBL-1 cells
showed no activation of JNK or p38. Orf50 expression was only in-
duced in the RTA-TREX BCBL-1 cells as expected.
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nication), who found that Orf49 expression peaks between 24
and 48 h using microarray analyses.
The cDNA encoded by Orf49 expressed a protein of 30
kDa. We determined that the Orf49-encoded protein is not
N-glycosylated or phosphorylated despite the presence of sev-
eral possible glycosylation and phosphorylation sites in the
coding sequence. However it is possible that the protein can be
phosphorylated but is resistant to calf intestinal phosphatase.
Additionally, the Orf49 protein was localized to both the nu-
cleus and the cytoplasm of cells as observed by immunofluo-
rescence and cell fractionation Western blots.
We next assessed the role of Orf49 in viral transcription. We
used promoter reporter assays to evaluate if Orf49 was in fact
able to induce expression from lytic viral promoters. Our re-
sults showed that Orf49 itself was not a potent transactivator
but was able to cooperate with Orf50 to increase Orf50-medi-
ated activation of the K8, Orf57 and vGPCR promoters. It is
important to note that the activation of these promoters by
Orf50 alone was already high ranging from 50-fold (Orf57) to
350-fold (vGPCR) over that of the empty vector. This strong
activation of Orf57, vGPCR, and K8 suggests that Orf49 syn-
ergizes with Orf50 to increase the efficiency of lytic reactiva-
tion. Indeed, Orf57 has been shown to bind Orf50 and induce
expression from the Orf50 promoter (23), suggesting that, in
vivo, induction of Orf57 could indirectly enhance Orf50 ex-
pression and thus lytic reactivation.
The K8 protein binds the oriLyt and is essential for lytic
replication (1), and hence, the increase in K-bZip expression
mediated by Orf49 could significantly enhance the efficiency of
lytic reactivation initiated by Orf50. Finally, the constitutively
activated viral G protein-coupled receptor is an early lytic gene
that plays important roles in angiogenesis. Thus, cooperative
induction of these three viral promoters by Orf49 and Orf50
has tangible biological consequences for host cells undergoing
lytic replication as well as the surrounding environment.
We have also identified a mechanism by which Orf49 in-
duces expression of K8, Orf57 and vGPCR. These promoters
all share AP-1 sites in addition to RTA-responsive elements.
Using CAT reporter assays we demonstrated that Orf49 can
augment c-Jun-mediated transcriptional activation and that
this activation was dose dependent. These results were further
validated by assessing phospho-c-Jun levels in the presence
and absence of Orf49. Expression of Orf49 increased phospho-
c-Jun levels compared to that of the vector controls. Orf50 has
been shown to increase the levels of total c-Jun in DG75 cells,
however, it did not induce c-Jun phosphorylation (40). To-
gether these findings could suggest a mechanism by which
Orf50 increases total c-Jun protein and Orf49 induces phos-
phorylation and activation of c-Jun, thus enhancing the total
c-Jun transcriptional activation potential in the cell.
Since c-Jun activation is dependent on c-Jun N-terminal
kinase, we also performed anti-phospho-c-Jun N-terminal ki-
nase Western blots and found that Orf49 can indeed activate
JNK. These results could indicate that c-Jun-mediated tran-
scriptional activation is induced by Orf49 through JNK activa-
tion. Interestingly, Orf49 also induced phosphorylation/activa-
tion of the p38 kinase. Both the JNK and p38 pathways are
activated by stress, growth factors and cytokines. They are
activated by the same mitogen-activated protein kinase kinase
kinases (MAP3Ks), share the MAP2K MKK4, and are often
coactivated (43). Signaling through both pathways can result in
proliferation, differentiation, or apoptosis although p38 activa-
tion is also involved in development, inflammation, and stress
responses.
KSHV vGPCR has also been shown to trigger the activation
of JNK and p38 (2), underscoring the significance of these
pathways during lytic replication. Because of the wide-ranging
effects of these pathways we wanted to assess the contribution
of each pathway to lytic reactivation. JNK and p38 inhibitors
blocked TPA-induced expression of early genes such as vGPCR
and Orf57 as well as late genes such as Orf62/minor capsid
protein. There was a marked decrease in the total amount of
Orf62/minor capsid protein detected in both JNK and p38
FIG. 8. JNK and p38 activation is necessary for lytic gene expres-
sion. A) Reverse transcription-PCR of total RNAs from TPA-induced
or mock-treated BCBL-1 cells treated for 24 h with the JNK inhibitor
SP600125 or the p38 inhibitor SB202190 was performed. PCRs using
vGPCR and Orf57 primers revealed that expression levels of these
early genes are inhibited by JNK and p38 inhibitors. However, expres-
sion of the Orf49 gene product was not inhibited by the presence of the
JNK or p38 inhibitor. In addition, levels of the latency gene LANA
were not affected by the JNK or p38 inhibitor. The human glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) transcript was used as
a loading control. B) JNK and p38 inhibition hinders late protein
synthesis. BC-1 cells were induced with TPA (or mock induced with
DMSO) and the JNK or p38 inhibitor. Cell lysates were harvested and
equal amounts of total protein were analyzed by Western blots using
antibody directed against the late protein Orf62/minor capsid protein.
The bottom panel shows an actin loading control.
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inhibitor-treated, lytically reactivated cell lysates, indicating
that signaling through both pathways can influence the amount
of late structural proteins produced.
KSHV Orf49 is the positional homologue of the Epstein-
Barr virus BRRF1 gene encoding the Na protein. Na has been
shown to encode a 34-kDa protein with early kinetics that is
induced by ZTA (34). Hong et al. reported that Epstein-Barr
virus Na functions in the reactivation of latent Epstein-Barr
virus by inducing lytic promoters and increasing the amount of
viral progeny released (13). They further showed that the
BRRF1 promoter was induced by ZTA through a CRE motif
(ZII) and that Na enhanced Epstein-Barr virus RTA’s ability
to induce ZTA, thus creating a self-reinforcing loop. Epstein-
Barr virus Na was also shown to activate c-Jun-mediated tran-
scription. These findings led to the identification of Na as a
transcription factor that activates ZTA expression through the
activation of c-Jun and cooperates with RTA (BRLF1) in re-
activation of Epstein-Barr virus from latency. However, since
KSHV K8, the Epstein-Barr virus ZTA homolog, cannot by
itself reactivate the virus from latency, it seems likely that the
main function of KSHV Orf49 is to augment Orf50 transacti-
vation of a subset of early promoters.
Thus, Orf49 represents an important member in the lytic
reactivation cascade that enhances transcription from key
Orf50-responsive promoters through the transcriptional acti-
vation of c-Jun and also activates the JNK/p38 kinase path-
ways, which are necessary for KSHV reactivation from latency
as well as viral replication.
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